Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3Terminated 1

Sponsor Class

NETWORK 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Dermatologic 1

Conditions

Uterine Cervical Neoplasms 3Sarcoma, Kaposi 3Pancreatic Neoplasms 3Neoplasms 3Neoplasms, Plasma Cell 2Multiple Myeloma 2Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sezary Syndrome 1Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Large Granular Lymphocytic 1Leukemia 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Head and Neck Neoplasms 1HIV Infections 1

Interventions

Zidovudine 9Doxorubicin 9Vincristine 6Bleomycin 6Interferon alpha-2 5Etoposide 5tecogalan 4Valganciclovir 4Semaxinib 4Liposomes 4Ritonavir 3Paclitaxel 3Nelfinavir 3Filgrastim 3Bevacizumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2sargramostim 2liposomal doxorubicin 2interferon alfa-n1 2Indinavir 2Docetaxel 2Didanosine 2Alitretinoin 2vesnarinone 1valspodar 1tocilizumab 1tin etiopurpurin 1pomalidomide 1pembrolizumab 1halofuginone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Sarcoma, Kaposi × Nelfinavir × Clear all
NCT03077451 2025-12-17

Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

AIDS Malignancy Consortium

Phase 2 Completed
36 enrolled 13 charts
Sarcoma

Sarcoma, Kaposi

NCT00003008 2023-06-15

Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma

Eastern Cooperative Oncology Group

Phase 2 Completed
33 enrolled
Sarcoma

AIDS-related Kaposi sarcoma, Sarcoma, Sarcoma, Kaposi

NCT00002185 2005-06-24

A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3

NIH AIDS Clinical Trials Information Service

Phase 2 Completed
20 enrolled
DermatologicSarcoma

Sarcoma, Kaposi, Skin Neoplasms, HIV Infections, AIDS-Related Opportunistic Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡